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Abstract
Background: Endometriosis are defined as a progesterone-resistance disease. Two
progesterone receptor (PR) isoforms, namely PR-A and PR-B, mediate the special
effects of progesterone. One of themost effective polymorphism in the promoter region
of PGR is the +331G/A.
Objective: The differential expression level of PR isoforms due to +331G/A poly-
morphism may be able to influence the function of progesterone and reduce the
susceptibility of endometriosis.
Materials and Methods: This analytic, case-control study was carried out at Royan
Institute, Tehran, Iran. Whole-blood samples were collected from 98 infertile women
undergoing laparoscopy for endometriosis and 102 healthy fertile women. After DNA
extraction, genotype frequencies were determined by polymerase chain reaction-
restriction fragment length polymorphism. Then, RNA was extracted from the selected
eutopic tissue samples of endometriosis patients. Analysis of PR-A and PR-B mRNA
expressions were performed using Real-time polymerase chain reaction.
Results: The frequency distribution of GG, GA genotypes in +331G/A polymorphism
was 98.04%, 1.96% in the patients and 97.96%, 2.04% in the control groups, respectively
(p = 0.968). Although our data did not show any significant association with +331G/A
in the patient and control groups, we were able to demonstrate significantly higher
expression level of PR-B and no significant lower expression level of PR-A isoforms in
patients by favoring GA to GG genotypes (p = 0.017, p = 0.731, respectively).
Conclusion: Our findings show that patients with GA genotypes had a higher
expression level of PR-B compared to patients with GG genotypes.
Key words: Endometriosis, Progesterone receptor A, Progesterone receptor B,
rs10895068.
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1. Introduction
Infertility reduces the quality of life for millions
of women worldwide, causing significant annual
costs in the health care system (1, 2). To our
knowledge, endometriosis involves 30–50% of
women with infertility (3). Endometriosis disease
is defined as a benign gynecological disorder,
which is characterized by the being of endometri-
otic lesions containing of functional endometrial
glands and stroma outside of the uterine cavity
(4, 5). Endometriosis affects natural fertility through
various approaches, including physical blocking
of fallopian tubes, endocrines, and oocyte defi-
ciency, like luteinized unruptured follicle syndrome,
impaired folliculogenesis, luteal phase defect, and
premature or multiple luteinizing hormone surges
(6, 7). However, the association of endometriosis
and infertility has been discussed yet and is still
unclear (6). The high level of activate macrophages,
prostaglandins, interleukin 1 (IL-1), tumor necrosis
factor (TNF) and proteases in the endometriosis
may have opposed effects on the ovulatory, sperm,
embryo, or fallopian tube, causing infertility (6, 7).
A further potential mechanism for these ‘inflamma-
tion activities’ mediates by an interaction between
the pro-inflammatory nuclear factor-κB (NF-κB)
transcription factor complex and sex steroid pro-
gesterone hormone in human myometrial cells (8).
In fact, endometriosis are known as a progesterone
resistance disease (9). The genomic effects of
progesterone upon target tissues are normally
mediated by nuclear Progesterone Receptor (PR)
isoforms specifically PR-A and PR-B (10). These
isoforms are encoded from a single gene by differ-
ential promoter usage on chromosome 11q22-q23
(10, 11). PR-A is a truncated (by 164 N terminal amino
acids) form of PR-B isoform (10). The capacity of
these isoforms to evaluate the transcriptional activ-
ity of progesterone plays a major role in the biology
of endometriosis (8, 9). Whereas PR-B isoform was
shown to stimulate transcriptional activity, PR-A
isoform seemed to act as a dominant repressor
of PR-B in many target tissues (9). Consequently,
altered PR-A/PR-B ratio might render responsive or
resistant to progesterone in specific target tissues,
which could be essential in pathogenesis and
inflammation activity of endometriosis.
Recently, A putative functional polymorphism
in the promoter region of the PGR gene has
been identified in the position +331 (G+331A)
(rs10895068) (11, 12), creating another TATA box,
which provides a specific transcriptional start site
by favoring high transcriptional production of PR-
B compared to PR-A isoform (11, 12). PR-B defi-
ciency isoform may also be main reason for
other consequences of progesterone resistance in
endometriosis (13, 14).
Our objective was to determine how the PR-
A/PR-B ratio alters via +331G/A polymorphism in
endometriosis because this alternation can affect
the capacity of progesterone response tomodulate
the expression of inflammatory mediators and
influence endometriosis disease.
2. Materials and Methods
2.1. Study populations
A total of 200 women, 98 infertile women
undergoing endometriosis were recruited from
July 2012 to March 2015 at Roran Institute, Iran.
All of these women with endometriosis confirmed
by laparoscopy and postoperative histology study
were included as the patient group. Our control
subjects were 102 healthy, fertile women (without
endometriosis) with at least one child, having regu-
lar cycles, and no evidence of any pathologic uter-
ine disorder. None of them had visible endometrial
hyperplasia or neoplasia, inflammatory or autoim-
mune disease, and endometriosis at the time of
clinical examination. None of the patients and
control subjects had received hormonal treatments
for at least three months prior to surgery. The
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distribution of the samples according to the mean
age and Body Mass Index was compared with
women with/without endometriosis (control group)
that showed no statistical differences (Table I).
2.2. Polymorphism study
2.2.1. Polymerase chain reaction condi-
tion
Whole-blood samples were collected from all
200 subject women. Genomic DNA was extracted
from whole peripheral EDTA-blood samples by
using the standard salting-out method from patient
and control samples (15). The DNA was stored
at 4∘C until analyzed. Polymerase chain reaction-
restriction fragment length polymorphism (PCR-
RFLP) was used to genotype the +331G/A promoter
SNP (Single Nucleotide Polymorphism). The PCR
primers were designed to amplify the specific PR
gene fragment. The expected product-size was
shown in Table II. The PCRs were performed in a
total volume of 30 μl containing 50 ng of genomic
DNA, 4 pmol of each primer, and 7.5 μl master
mix (Amplicon Taq DNA Polymerase 2x master mix
(red), 1.5 mM MgCl2). PCR protocol consisted of
three steps: primary denaturation at 94∘C for 4
min continued by 33 cycles at 94∘C for the 30 s,
annealing at 67∘C for 30 sec, extension at 72∘C for
1 min, and a final extension at 72∘C for 10 min. After
amplification, the products of PCRs were assessed
by 1.2% ultra-pure agarose gel electrophoresis and
visualized by ethidium bromide staining followed
by Molecular Imager® Gel Doc𝑇𝑀 XR+.
2.2.2. RFLP
Identification of +331G/A promoter polymor-
phism was based on RFLP technique of fragments
that had been amplified by PCR. The amplified
PCR fragment was digested with N1aIV restric-
tion endonuclease (Fermentase Biolabs, MA, USA)
overnight at 37∘C. The size of the digestion prod-
ucts is evaluated by 1.7% ultra-pure agarose gel
electrophoresis that was explained earlier (Figure
1); 10% of samples of different genotypes were
randomly sequenced by aDNA sequencing Sanger
method (Sequetech Inc., USA) to confirm genotyp-
ing results. Sequenced results were blasted against
the ancestral sequence in NCBI (http://blast.ncbi.
nlm.nih.gov.com) and diagrams were analyzed via
Finch TV software version 1.4.0.
2.3. Expression assay
Out of 98 infertile women with endometrio-
sis, eutopic (endometrium) tissue samples were
recruited from eight women, including two patients
with GA (one of themwas in proliferative phase and
another one was in secretory phase of the cycle)
and six patients with GG genotypes. According
phases of the cycle in patients with GA genotypes,
three of tissue samples were recruited in prolif-
erative phase and another half were in secretory
phase of the cycle in patients with GG genotypes.
Tissue samples were obtained by pipelle from all
same patients.
2.4. RNA extraction and cDNA prepa-
ration
In brief, RNA was isolated from frozen tissue
samples using Trizol (Invitrogen, USA) following the
manufacturer’s recommendations. One microgram
of genomic DNA for each sample was treated with
RNase free DNase I (#EN0521-Fermentas, Thermo
scientific, Germany), incubation at 37∘C for 30 min.
DNase I enzyme was inactivated by EDTA (50
mM, Fermentas, Thermo Scientific, Germany) and
incubation at 65∘C for 7 min. Complementary DNAs
(cDNAs) were prepared from one microgram of
total RNA for each sample by One-step RT-PCR,
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using first-strand cDNA synthesis kit (K1632- Fer-
mentas, Thermo Scientific, Germany). Synthesized
cDNA was stored at -20∘C until used.
2.5. Quantitative real-time PCR
Analysis of PR-A and PR-B mRNA expressions
were performed using SYBR® Premix Ex Taq II
(Applied Biosystems, USA) on a Light Cycler Sys-
tem, 7500 software version 2.0.1 (Applied Biosys-
tems, 7500, USA) as recommended by the manu-
facturer. The specific primers used for amplification
of PR-A, PR-B, and β-actin (as a housekeeping
gene) were designed using specific primer analysis
software the Gene Runner (version 3.05) and Perl
Primer software (version v1.1.20). These sequences
were analyzed by Nucleotide Blast and Primer-
Blast in the NCBI database (http://blast.ncbi.nlm.
nih.gov/). The primers used in this study and the
expected product-sizes from them were shown in
Table II. Primers were purchased by order from
Pishgam Co, Iran.
Each assay was carried out in a final volume
of 20 µl containing 10 µl SYBR® Premix Ex Taq II
(consisting of Taq DNA polymerase reaction buffer,
dNTP mix, SYBR Green II, MgCl2, and Taq DNA
polymerase), 5 pmol (Pico mole) of β-actin, PR-A
or PR-B primers, 25 ng/µl of synthesized cDNA
and water to reach. Each sample was analyzed
in duplicate in three independent real-time RT–
PCR assays. The amplification program consisted
of the following three steps. Cycling conditions
included incubation at 95∘C for 10 min, and 40
cycles of 95∘C for 15 sec (denaturation), 60∘C
for 1 min (annealing) for β-actin, PR-A, and PR-B.
Finally, the temperature was raised gradually from
60∘C to 95∘C for 15 sec and 1 min at 60∘C for
melting curve analysis. After each run, a melting
curve analysis was achieved to verify the specificity
of the PCR reaction. All samples were retested
with a cycle threshold coefficient of variation value
higher than one degree. To confirm the melting
curve results, we assayed representative samples
of the real-time PCR products on 2% ultra-pure
agarose (Invitrogen, USA) gel electrophoresis (Paya
Pazhoh Pars, Iran), and stained them with ethidium
bromide (Sigma Aldrich, USA) prior to visualization
on a Molecular Imager® Gel Doc𝑇𝑀 XR+ (BioRad,
USA).
Table I: Clinical characteristics of groups.
Groups Number Age (yr) BMI (kg/m2) Stage (n) During of
Infertility
Controls 102 29 ± 11 27.6 ± 8.1 - -





P-value - p > 0.05 p > 0.05 – –
Note: Data are expressed as mean ± SEM and values in parentheses are percentages; BMI: Body mass index
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Table II: Primer sequences of +331G/A SNP, PR-A, PR-B and β-actin.













Figure 1: The RFLP pattern of PGR promoter +331G/A polymorphism showing two types of homozygotes (GG) and a heterozygote
(GA).
2.6. Ethical consideration
This population-based study was approved by
the Department of Genetics in Royan Institute,
Tehran, Iran. Approval was obtained from the
Institutional Research Ethics Board. The Ethics
Committee of Royan Institute approved this study
(No: EC/93/1047). All participants provided a signed
informed consent.
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2.7. Statistical analysis
PGR genotypes and population’s clinical
information were compared between groups
(endometriosis and control) using independent
t-test and chi-square test. The expression levels
of PR-A and PR-B in patients bearing GA or GG
genotypes were compared using Wilcoxon in
extracting eutopic samples. Statistical analysis
was conducted using SPSS software (Statistical
Package for the Social Sciences, version 16.0,
SPSS Inc., Chicago, IL, USA). All statistical tests
were two-tailed and a p < 0.05 was considered
statistically significant.
3. Results
3.1. Polymorphism of PGR promoter
The frequency of distribution of GG and GA
genotypes in +331G/A polymorphism in 200 blood
samples of patients was 98.04% and 1.96%, and in
the control group, it was 97.96%, 2.04%, which was
not significantly different (p = 0.968).
Eight of ninety-eight patients underwent tissue
sampling for expression study, the results of a study
of their polymorphism showed two and six patients
with GA and GG genotypes, respectively.
3.1.1. The expression of PR isoforms via
+331G/A promoter polymorphism
Our results demonstrated significantly
higher expression level of PR-B isoform in the
endometrium of patients bearing GA compared
to subjects with GG genotypes in +331G/A
polymorphism of PGR gene (0.0029 ± 0.0003
vs. 0.0019 ± 0.0003; p = 0.017) (Figure 2). The
expression level of PR-A in eutopic endometrium
of patients was not significantly different between
GA and GG genotypes (138.27 ± 87.84 vs. 155.01 ±
57.50; p = 0.731) (Figure 3).
Figure 2: The expression level of PR-B isoform via +331G/A promoter polymorphism in endometriosis.
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Figure 3: The expression level of PR-A isoform via +331G/A promoter polymorphism in endometriosis.
4. Discussion
4.1. The effects of progesterone recep-
tors in endometriosis
Progesterone acts by binding to and activating
PR-A and PR-B isoforms expressed in target tis-
sues (16). These isoforms are functionally differ-
ent and encoded from a single gene by differ-
ential estrogen-regulated promoters (17). PRs are
ligand-induced transcription factors (16, 18). These
isoforms contain of DNA-binding domain (DBD),
inserted among an upstreamN-terminal region that
consists the activation (AF) and inhibitory (IF) roles,
a downstream hinge region and C-terminal ligand-
binding domain (LBD) (19). Just only deference
of PR-A and PR-B isoforms is that PR-B isoform
contain an extra 164 amino acid far N-terminal
region, called the “B-upstream segment” (BUS) by
advising AF3 activity (16). This part is missing in PR-
A isoform. Thus, the global structural differences
between PR-B and PR-A are distended from the
BUS that controls their properties (16). Several
recent studies are indicative of resistance to pro-
gesterone action in endometriosis (14). The effects
of progesterone upon target tissues are generally
mediated through PR-A/PR-B ratio to modulate the
expression of genes, especially the inflammation-
associated transcription factor NF-κB (8, 10). The
molecular mechanism of progesterone resistance
in endometriosis may be related to reduction,
or lack, of the PRs, especially PR-B isoforms (9,
14). In normal endometrium, progesterone induces
the expression of the enzyme 17β-hydroxysteroid
dehydrogenase type 2 (17β-HSD-2), which metab-
olizes the biologically active estrogen estradiol (E2)
to estrone (E1) (20). Progesterone does not induce
epithelial 17β-HSD-2 expression may be due to
the lack of PR-B in the endometriotic lesion (14,
20). This defect causes the deficient metabolism
of E2 and increases local concentrations of E2 in
endometriosis (20). The best-defined mitogen for
the growing and inflammation activity of ectopic
lesions is active E2 (14). On the other hand,
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progesterone exerts anti-inflammatory actions by
inhibiting the pro-inflammatory NF-κB transcrip-
tion factor complex in human myometrial cells
(8, 21). Progesterone increases expression of
inhibitor-κBα, a repressor of NF-κB transcription
factor, via PR-B isoform, therefore inhibits pro-
inflammatory gene expression (8). The crosstalk
between oocytes and sperms may is blocked
during fertilization by these inflammation activi-
ties due to progesterone resistance and reduced
sperm affinity to the zona pellucida through TNF,
IL-1, migration inhibitory factor, oxidative stress,
and the RANTES cytokine in endometriosis (6,
22). The high level of activate macrophages,
prostaglandins, IL-1, TNF, and proteases in the
endometriosis could have opposing effects on
the evolution of ovulatory, sperm, and embryo
causing infertility in endometriosis (6, 22). In the
present study, we demonstrated the expression
levels of PR-A and PR-B via +331G/A promoter
polymorphism in endometriosis. Altered PR-A/PR-
B ratio via +331G/A polymorphism may affect the
capacity of progesterone response to modulate
the expression of inflammatory mediators and
influence the pathogenesis of the disease.
4.2. The association between a PGR
promoter polymorphism and
endometriosis
Recently, A putative new functional polymor-
phism has been recognized in the promoter region
of the PGR gene in the position +331 (G+331A)
(12). The +331A allele makes a potential TATA-box,
creating a specific transcriptional start site, that
increases expression level of PR-B isoform (12, 23).
Consequently, it could be reason of high expres-
sion level of PR-B isoform by favoring A allele. Near
et al have been reported a decreased level of PR-
A to PR-B expressions in the +331 A allele and
if the reported association with endometriosis is
confirmed, it would suggest that this ratio could be
important in endometriosis (11). To our knowledge,
the biochemical studies suggest that +331G/A PGR
polymorphism may contribute to endometrial can-
cer risk through increased PR-B-dependent stimu-
lation of endometrial cell growth (24). An alteration
in the PR-A/PR-B ratio by the overexpression of PR-
B isoform due to +331G/A promoter polymorphism
may lead to an increased risk of developing overall
female cancer risk (25). Although Berchuck and
colleagues have suggested a reduced risk of
endometriosis associated with A allele of +331 SNP
(26), Treloar et al found no association (27). Van
Kaam et al informed a low risk of endometriosis in
women who had +331A allele compared to women
carried +331G once (28), but this observation is
in the directional conflict with reported that was
studied by Gentilini and colleagues (29). Part of the
aim of this study was to investigate the association
between the putative functional promoter +331G/A
SNP and endometriosis. Here we present that
the results of our analysis suggest that +331G/A
in the promoter region of PGR is not associated
with endometriosis. However, further research is
warranted to clarify the role of the +331G/A variant
in endometriosis.
4.3. The expression of PR-A and PR-
B isoforms via +331G/A polymor-
phism in endometriosis
We observed a significant association between
the +331G/A polymorphism and the expression
level of PR isoform. Our results showed that
patients with GA genotype had significantly high
expression level of PR-B compared to patients
with GG genotypes in +331G/A promoter polymor-
phism. The effects of progesterone depend on tight
regulation of the PR-A and -B isoform balance.
Altered PR-A/PR-B ratio modifies progesterone
action via differential regulation of specific proges-
terone response targeted genes that may progress
endometriosis disease. Progesterone reduces the
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expression of pro-inflammatory genes when the
PR-A/PR-B ratio favored PR-B and improves these
gene expressions by favoring PR-A isoform (21,
30). As a consequence, the specific genomic effect
of progesterone responsiveness is equally related
to the PR-A/PR-B ratio and PR-A isoform is an
endogenous repressor of PR-B (8). Attia et al
have reported a decreased concentration of PR-
B isoform in ectopic lesions, which would be
consistent with a protective role of +331A allele
that increase PR-B isoform level and therefore may
could compensate progesterone responsiveness
(9, 11). Consequently, the presence of the +331A
allele is hypothesized to lead to a greater effect
of progesterone. The increased production of PR-
B and the decreased level of PR-A isoforms by the
+331A allele may be able to influence the function
of progesterone via PR-A/PR-B ratio alternation and
reduce the liability and symptoms of endometriosis.
5. Conclusion
In summary, we were interested to evaluate the
correlation between the differential expression of
PR isoforms via +331G/A promoter polymorphism
of PGR in endometriosis. Although we did not
find any association between the +331G/A SNP
and endometriosis, we observed a significant
relation between expression level of PR isoform
and +331G/A polymorphism in endometriosis. It is
known that endometriosis affects the function of
oocyte and sperm through hampering the crosstalk
between oocytes and sperms during fertilization by
decreasing sperm binding to the zona pellucida.
This hypothesis may be correlated further with
inflammation activities due to progesterone resis-
tance in endometriosis. We found overexpression
level of PR-B via +331G/A polymorphism, as a con-
sequence of altered PR-A/PR-B ratio in endometrio-
sis. This alternation may be able to affect the
function of the follicular microenvironment, oocyte,
and embryo cross-talking quality that may be able
to reduce infertility in endometriosis.
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